The California Institute for Regenerative Medicine (CIRM) announces that it is investing $15.9 million in a therapy to tackle ALS.
Browsing: Movement disorders
Dr Lin tells Lauren Pulling (Editor, NC) about his work as a pediatric neurologist, and recent advances in deep brain stimulation for infants.
Tom Naughton introduces the circuitry underlying Parkinson’s disease, and how our understanding and new techniques have advanced hand-in-hand to bring us to where we are now.
Dr Vitek discusses the Neuromodulation Research Center, progression in the field, and the biggest challenges associated with developing new neuromodulation therapies for conditions such as Parkinson’s disease.
The enzyme asparagine endopeptidase could be a key mediator in the cleavage and aggregation of alpha-synuclein in Parkinson’s disease.
October babies are more likely to develop the syndrome, according to a study presented at the Congress of the European Academy of Neurology (Amsterdam, The Netherlands).
Researchers have provided evidence indicating that patients with hypertension suffer from more severe Parkinson’s disease than those with normal blood pressure.
A new study has demonstrated the potential of excitatory intermittent theta burst stimulation (iTBS) for reducing spasticity in patients with spinal cord injury.
Researchers have found the first evidence that autoimmunity plays a role in Parkinson’s disease, showing that T cells recognize α-synuclein peptides.
An international research team have shown that gene editing reverses Huntington’s symptoms without off-target effects in a mouse model.